Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21034080 | 0.85 | KMT2A (0.47) | KMT2AMEN1ALDH1A1CA1CA2 | |
| SCHEMBL12260657 | 0.84 | ATM (0.46) | KMT2AMEN1ALDH1A1CA1CA2 | |
| SCHEMBL18493202 | 0.83 | KMT2A (0.50) | KMT2AMEN1ALDH1A1CA1CA2 | |
| SCHEMBL6404528 | 0.83 | KMT2A (0.51) | KMT2AMEN1ALDH1A1CA1CA2 | |
| SCHEMBL27471238 | 0.83 | GAA (0.49) | KMT2AMEN1ALDH1A1CA1CA2 | |
| SCHEMBL420634 | 0.83 | KMT2A (0.51) | KMT2AMEN1ALDH1A1CA1CA2 | |
| SCHEMBL12585668 | 0.81 | CTNNB1 (0.47) | KMT2AMEN1ALDH1A1GAAPOLB | |
| SCHEMBL11023514 | 0.81 | KMT2A (0.47) | KMT2AMEN1ALDH1A1CA1CA2 | |
| SCHEMBL4682656 | 0.81 | TDP1 (0.41) | KMT2AMEN1ALDH1A1GAAATM | |
| SCHEMBL30628227 | 0.79 | KMT2A (0.48) | KMT2AMEN1ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106103439-B | 2,7- diaza spiro [3.5] nonane compound | 瑞敏德股份有限公司 | 2019-03-08 | — | — | CN | disclosed |
| EP-3119782-B1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2018-01-31 | — | — | EP | disclosed |
| US-9750745-B2 | 2,7-diazaspiro[3.5]nonane compounds | REMYND NV (BE) | 2017-09-05 | — | — | US | disclosed |
| US-20170157137-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2017-06-08 | — | — | US | disclosed |
| EP-1368295-B1 | PROCESS FOR THE MANUFACTURE OF PHENYLACETIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9617264-B2 | 2,7-diazaspiro[3.5]nonane compounds | REMYND NV (BE) | 2017-04-11 | — | — | US | disclosed |
| EP-3119782-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| US-20170015665-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2017-01-19 | — | — | US | disclosed |
| CN-106103439-A | 2,7 diaza spiros [3.5] nonane compound | 瑞敏德股份有限公司 | 2016-11-09 | — | — | CN | disclosed |
| WO-2015140132-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| CN-101868457-A | (3-hydroxy-4-amino-but-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for use in therapy | COMENTIS INC | 2010-10-20 | — | — | CN | disclosed |
| CN-101821238-A | Suppress the active isophthaloyl sulfonamide derivatives of beta-secretase (BETA-SECRETASE) | COMENTIS INC | 2010-09-01 | — | — | CN | disclosed |
| CN-100450994-C | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | CN | disclosed |
| CN-1915964-A | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-21 | — | — | CN | disclosed |
| CN-1809573-A | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-07-26 | — | — | CN | disclosed |
| CN-1250528-C | Cyclic nitrones and pharmaceutical compositions containing them | AWENTIS PHARMACEUTICAL INC (US) | 2006-04-12 | — | — | CN | disclosed |
| CN-1729158-A | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | CN | disclosed |
| CN-1500787-A | Cyclic nitrones and pharmaceutical compositions containing them | ���µ�˹ҩ�﹫˾ | 2004-06-02 | — | — | CN | disclosed |
| CN-1500779-A | Cyclic nitrones and pharmaceutical compositions containing them | ���µ�˹ҩ�﹫˾ | 2004-06-02 | — | — | CN | disclosed |
| CN-1196050-A | Cyclic nitrones and pharmaceutical compositions containing them | HOECHST MARION ROUSSEL INC (US) | 1998-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157137-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | PSEN1, MAPT, PSEN2 | KMT2A 4531/4885MEN1 1633/4885ALDH1A1 1771/4885 |
| US-20170015665-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | PSEN1, MAPT, PSEN2 | KMT2A 4531/4885MEN1 1633/4885ALDH1A1 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.